DURECT, based in Cupertino, California, develops investigational therapies, including Larsucosterol for alcohol-associated hepatitis. Its FDA-approved products include POSIMIR and PERSERIS, while employing 48 staff since its 2000 IPO.
Based on our analysis, Durect Corporation has received an overvalued rating of 1 out of 5 stars from Cashu, primarily due to its underperformance in key financial metrics compared to its sector.
One significant concern is Durect's net profit margin, which stands at -323.16, indicating that the company is incurring substantial losses relative to its revenue. In contrast, the sector average for net profit margin is significantly better at -138.75. A negative net profit margin suggests that Durect is struggling to convert sales into profit, raising concerns about its operational efficiency.
Additionally, the company's return on equity (ROE) is -186.86, far worse than the sector average of -74.35. ROE measures a company's ability to generate profit from shareholders' equity, and a negative figure indicates that the company is not effectively utilizing its investors' capital, signaling potential issues in management or business strategy.
Furthermore, Durect's return on assets (ROA) is -61.13 compared to the sector's -47.85. ROA reflects how efficiently a company is using its assets to generate earnings, and a negative return indicates that Durect is failing to generate profits from its asset base, which raises red flags for potential investors.
These financial ratios highlight substantial operational challenges that Durect faces, contributing to its overvalued rating. Investors should be cautious and consider these factors in their evaluation of the company.
This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.
📡️ Health Care
Overvalued
More Signals
Feature in Progress
This section is under development. Check back soon for updates!